Effusion Cytology
The value of cytology in distinguishing malignant mesothelioma: An institutional experience of 210 cases reclassified according to the International System for Reporting Serous Fluid Cytopathology (ISRSFC)
Cytopathology 2021 May 28 [Link] Patrizia Straccia, Daniele Magnini, Rocco Trisolini, Filippo Lococo, Marco Chiappetta, Alessandra Cancellieri Abstract Objective: Malignant mesothelioma (MM) is usually diagnosed by histological examination of tissue samples; however, effusion cytology offers an opportunity to identify a strong possibility for mesothelioma diagnosis at an early stage. We conducted a retrospective analysis of…
Read MoreDiagnostic utility of BAP1 for malignant pleural mesothelioma in pleural fluid specimens with atypical morphology
Cytopathology 2021 May 25 [Link] Amber Louw, Y C Gary Lee, Nathan Acott, Jenette Creaney, Chris van Vliet, Siaw Ming Chai Abstract Objective: To assess the utility of BRCA1-associated protein 1 (BAP1) immunohistochemistry (IHC) for the diagnosis of malignant pleural mesothelioma (MPM) in fluid samples with atypical cytology. Methods: Pleural fluid samples with an atypical…
Read MoreTesting for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology
Cancer Cytopathology 2020 July 17 [Link] Martin Chevrier, Sara E Monaco, Jacob A Jerome, Francoise Galateau-Salle, Andrew Churg, Sanja Dacic Abstract Background: A number of ancillary tests have been developed that aid in the diagnosis of mesothelioma in cytology specimens. The aim of this retrospective study was to determine whether testing for BAP1 and CDKN2A/p16…
Read MoreGenomic-based Ancillary Assays Offer Improved Diagnostic Yield of Effusion Cytology With Potential Challenges in Malignant Pleural Mesothelioma
Pathology International 2020 June 15 [Link] Yoshiaki Kinoshita, Makoto Hamasaki, Shinji Matsumoto, Masayo Yoshimura, Ayuko Sato, Tohru Tsujimura, Toshiaki Kamei, Kunimitsu Kawahara, Kazuki Nabeshima Abstract BRCA1-associated protein 1 (BAP1) or methylthioadenosine phosphorylase (MTAP) immunohistochemistry (IHC) or 9p21 fluorescence in situ hybridization (FISH) are useful for the diagnosis of malignant pleural mesothelioma (MPM). However, the effect…
Read MoreHEG1, BAP1, and MTAP Are Useful in Cytologic Diagnosis of Malignant Mesothelioma With Effusion
Diagnostic Cytopathology 2020 May 22 [Link] Kenzo Hiroshima, Di Wu, Shinji Hamakawa, Shingo Tsuruoka, Daisuke Ozaki, Hideki Orikasa, Mizue Hasegawa, Eitetsu Koh, Yasuo Sekine, Yoko Yonemori, Kazuki Nabeshima, Shoutaro Tsuji, Yohei Miyagi, Kohzoh Imai Abstract Background: The specificity and sensitivity of HEG1 for malignant mesothelioma (MM) is high. The use of BAP1/MTAP immunohistochemistry (IHC) is…
Read MoreEffusion cytology of malignant mesothelioma enables earlier diagnosis and recognizes patients with better prognosis.
Diagnostic Cytopathology 2020 February 20 [Link] Abd Own S, Höijer J, Hillerdahl G, Dobra K, Hjerpe A Abstract A conclusive diagnosis of malignant mesothelioma (MM) can be based on effusion cytology using the guidelines for the cytopathologic diagnosis of epithelioid and mixed-type MM. Briefly, the diagnosis is obtained when the mesothelial phenotype of malignant cells…
Read MoreCytoplasmic MTAP expression loss detected by immunohistochemistry correlates with 9p21 homozygous deletion detected by FISH in pleural effusion cytology of mesothelioma.
Histopathology 2019 April 8 [Link] Hamasaki M, Kinoshita Y, Yoshimura M, Matsumoto S, Kamei T, Hiroshima K, Sato A, Tsujimura T, Kawahara K, Nabeshima K Abstract Malignant pleural mesothelioma (MPM) is an aggressive neoplasm with poor prognosis. Diagnosis includes verification of mesothelial origin and discrimination of MPM from reactive mesothelial hyperplasia (RMH) or reactive mesothelial…
Read MoreWhat’s new in mesothelioma
Pathologica 2018 March [Link] Ascoli V, Murer B, Nottegar A, Luchini C, Carella R, Calabrese F, Lunardi F, Cozzi I, Righi L Abstract Malignant pleural mesothelioma is a neoplasm characterized by a very poor prognosis and medico-legal implications. Diagnosis, prognosis and therapy are often challenging and include several issues. Cytological diagnosis is frequently the first…
Read MoreA second case of pericardial mesothelioma mimicking systemic lupus erythematosus in the literature in over 30 years: a case report
Journal of Medical Case Reports 2017 March 29 [Link] Mensi C, Romano A, Berti A, Dore R, Riboldi L Abstract BACKGROUND: Mesothelioma is a rare neoplasm which commonly develops in the pleura of people exposed to asbestos. Pericardial mesothelioma accounts for only 0.7 % of all malignant mesotheliomas and it usually presents with pericardial effusion,…
Read MoreThe importance of EZH2 and MOC-31 expression in the differential diagnosis of benign and malignant effusions
Diagnostic Cytopathology 2016 December 26 [Epub ahead of print] [Link] Sadullahoglu C, Nart D, Veral A Abstract BACKGROUND: All malignant tumors may spread throughout the pleural, peritoneal, and pericardial cavities. The presence of tumor cells in serosal fluid is a poor prognostic indicator. It may be difficult to differentiate nuclear atypia of mesothelial cells due…
Read More